FHS researchers awarded over $11M in funding from the CIHR
Researchers in the Faculty of Health Sciences (FHS) have been awarded a total of $11.59M in funding from the Canadian Institutes of Health Research (CIHR). The funding is divided across 12 research projects (ten fully funded and two $100K priority announcement grants), each of which is led by an FHS faculty member, giving rise to a success rate of 26.3% compared to 15% nationally. The grants come as a result of the Fall 2020 CIHR Project Competition, a program designed to capture and support ideas with the greatest potential to advance health-related knowledge in Canada.
The funded FHS projects are as follows:
Sheela Abraham (Biomedical and Molecular Sciences; Queen’s Cancer Research Institute) - Elucidating the role extracellular vesicles play in leukaemogenesis, $1,071,000
Tricia Cottrell (Pathology and Molecular Medicine; Queen’s Cancer Research Institute) - Immunophenotyping Malignant Pleural Mesothelioma: Identifying Predictive and Prognostic Biomarkers for Combinatorial Immunotherapy, $872,865
Kerstin de Wit (Emergency Medicine) - PEITHO-3. Reduced-dose thrombolytic treatment for patients with higher-intermediate risk acute pulmonary embolism, $478,125
Vincent DePaul & Catherine Donnelly (Rehabilitation Therapy; Health Services and Policy Research Institute) - Fostering healthy aging in naturally occurring retirement communities: a mixed methods explanatory case study, $1,583,288
Jason Gallivan (Biomedical and Molecular Sciences; Centre for Neuroscience Studies) – Investigating the role of cognitive brain networks in human motor learning, $734,400
Ian Gilron (Anesthesiology & Perioperative Medicine) – The PRECISE trial – Pain Relief Combination Intervention StratEgies, $100,000
Michael Green (Family Medicine) & Ian Gilron (Anesthesiology & Perioperative Medicine) - Development of a validated method to identify patients with chronic pain in electronic medical records and administrative health data to advance clinical research and patient care, $673,200
Annette Hay (Medicine; Canadian Cancer Trials Group) - Randomized Phase 3 Evaluation of Lower Dose (3-2-1 Strategy) vs. Full Dose of Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia, $100,000
Amer Johri (Medicine; Translational Institute of Medicine) - Intraplaque Composition Combined with Stress Echo for Cardiac Risk Stratification, $918,000
Wendy Parulekar (Oncology; Canadian Cancer Trials Group) - SPECT-CT Guided ELEctive Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial, $3,203,435
Michael Rauh (Pathology and Molecular Medicine) - Dysregulation of TET2 and DNMT3A promotes pulmonary arterial hypertension (PAH) through inflammation: A new mechanism of PAH, $891,225
Chandrakant Tayade (Biomedical and Molecular Sciences) - Investigating the role of endocannabinoids in endometriosis pathophysiology and determine efficacy of cannabinoids as a novel therapeutic modality, $868,275
